The President signing off on “Advancing Hope Act of 2016,” which modifies the FDA’s priority review voucher program for rare pediatric diseases means an extension of the program through the end of the year, for now.
Even more importantly, this means that between now and December 31st, Congress will examine and deliberate ways to amend the program and extend it past 2016.
The sign off also clarifies one of the more controversial aspects of the bill - the definition of “rare pediatric diseases."
Read the full content at the original LinkedIn post.